Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

3 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
6 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.

Drug survival longer with etanercept vs other TNFi for rheumatoid arthritis

29 Apr 2020

There are more rheumatoid arthritis (RA) patients receiving etanercept (ETN) who remain on treatment compared with those taking other tumour necrosis factor inhibitors (TNFi) after >12 months of follow-up, reports a study.

The investigators conducted a systematic literature review and estimated drug survival (proportion of patients still receiving treatment) at 12 and 12–24 months of follow-up by summing proportions of patients continuing treatment and dividing by number of studies. Metaprop was used to estimate drug survival at ≥36 months of follow-up.

In total, 170 publications were included. In the first-line setting, drug survival with ETN, infliximab (IFX) or adalimumab (ADA) at 12 months was 71 percent, 69 percent and 70 percent, respectively, while the corresponding rates at 12–24 months were 63 percent, 57 percent and 59 percent.

In the second-line setting, drug survival at 12 months was 61 percent with ETN, 69 percent with IFX and 55 percent with ADA, while the corresponding rates at 12–24 months were 53 percent, 39 percent and 43 percent.

At ≥36 months, drug survival in the first-line setting was 59 percent (95 percent confidence interval [CI], 46–72) with ETN, 49 percent (95 percent CI, 43–54) with IFX and 51 percent (95 percent CI, 41–60) with ADA, while the corresponding rates in the second-line setting were 56 percent (95 percent CI, 52–61), 48 percent (95 percent CI, 40–50) and 41 percent (95 percent CI, 36–47).

Discontinuation at 36 months of follow-up was 38–48 percent with ETN, 42–62 percent with IFX and 38–59 percent with ADA. On the other hand, data were scarce for certolizumab pegol and golimumab.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

3 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
6 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.